RGNT News & Events

Regentis Biomaterials announced a collaboration with Humanitas Research Hospital in Milan, Italy,. This collaboration is currently in the process of being formalized, is expected to support the Company's expanding clinical activities in Europe where GelrinC already has CE Mark approval in the treatment of knee cartilage repair and further strengthen engagement with leading orthopedic surgeons across the European Union.

Regentis Biomaterials has developed a new manufacturing process for its lead product, GelrinC, an off-the-shelf hydrogel synchronized erosion and resorbable implant for the treatment of painful injuries to focal articular knee cartilage. The proprietary new process does not require the use of organic solvents which are not only flammable and toxic but also take up a major portion of the manufacturing process volume. This new solvent-free process more than quadruples production yield per batch. Regentis has filed patents worldwide for its solvent-free GelrinC manufacturing process that have already been granted in India, China and Israel, and is pending in the US. GelrinC has CE Mark approval in the European Union and Regentis is conducting a pivotal FDA study which has completed over 50% enrollment.

Regentis Biomaterials announced the appointment of Dr. Galit Reske as Chief Medical Officer. Dr. Reske brings extensive experience in clinical development, regulatory strategy, and global clinical operations across the United States, Europe, and Israel, with a particular focus on cartilage repair and osteochondral treatments. From 2017 to 2026, Dr. Reske served as Director of Clinical Operations at CartiHeal, where she played a central role in the clinical and regulatory advancement of Agili-C, a novel cartilage and osteochondral repair implant.